Emilio Lecona
New York University
17 Papers
78 Citations
Emilio Lecona is an academic researcher from New York University. The author has contributed to research in topics: DNA replication & Control of chromosome duplication. The author has an hindex of 10, co-authored 16 publications.
Chat about Author
Papers
Targeting ATR in cancer
TL;DR: Insight is provided into the potential of targeting the replication stress response in cancer and the strategy of inhibiting ataxia telangiectasia and Rad3-related protein (ATR) and the need for reliable biomarkers to enable patient stratification are discussed.
301
Replication stress and cancer: it takes two to tango.
TL;DR: The links between replication stress (RS) and cancer are reviewed, which provide a rationale for the use of ATR and Chk1 inhibitors in chemotherapy, and the evidence showing that tumors with high levels of RS are dependent on a proficient RS-response, and therefore vulnerable to ATR or Chk 1 inhibitors is summarized.
141
Efficacy of ATR inhibitors as single agents in Ewing sarcoma
Maria Nieto-Soler,Isabel Morgado-Palacin,Vanesa Lafarga,Emilio Lecona,Matilde Murga,Elsa Callen,Daniel Azorín,Javier Alonso,Andrés J. López-Contreras,André Nussenzweig,Oscar Fernandez-Capetillo +10 more
TL;DR: It is shown that ES suffer from high endogenous levels of RS, rendering them particularly dependent on the ATR pathway, and ATR inhibitors are identified as a potential therapy for Ewing Sarcomas.
Interactions with RNA direct the Polycomb group protein SCML2 to chromatin where it represses target genes
Roberto Bonasio,Emilio Lecona,Varun Narendra,Philipp Voigt,Fabio Parisi,Yuval Kluger,Danny Reinberg +6 more
TL;DR: It is shown thatSCML2A, an SCML2 isoform tightly associated to chromatin, contributes to PRC1 localization and also directly enforces repression of certain Polycomb target genes, pointing to a role for ncRNAs in regulating SC ML2 function and suggest that SCML 2 participates in the epigenetic control of transcription directly and in cooperation withPRC1.
USP7 limits CDK1 activity throughout the cell cycle
Antonio Galarreta,Pablo Valledor,Patricia Ubieto-Capella,Vanesa Lafarga,Eduardo Zarzuela,Javier Munoz,Marcos Malumbres,Emilio Lecona,Oscar Fernandez-Capetillo +8 more
TL;DR: In this article, the deubiquitinase USP7 inhibitors induce a widespread activation of CDK1 throughout the cell cycle, which leads to DNA damage and is toxic for mammalian cells.
28